ftInvstr
MAXIND · Healthcare ₹150.45 -1.08% Mkt Cap ₹794 Cr

MAXIND

Healthcare Medical Care Facilities
₹150.45
-1.08% today · 30d -12.02%
as of 2026-09-04
Price · Daily Candles
“MAXIND grapples with severe losses as quarterly profit plunges, prompting rights issue amid FII/Promoter stake cuts.”
MAXIND reported a Q4 2025 net loss of ₹43 Cr, with annual revenue declining by 29.22% to ₹145 Cr in FY25. The company's ROCE stands at a substantial -24.0%, and it trades at a Price-to-Book of 1.7 despite ongoing financial challenges.
BULL CASE
+Quarterly revenue for Q4 2025 showed a 24.06% YoY increase to ₹43 Cr, indicating some recovery.
+Forecasts for Free Cash Flow (FCF) show moderate to strong predictions, with one-year FCF rankings ranging from neutral (0.638) to strong (0.664) across different timeframes.
+Despite negative operating profit in Q4 2025, operating profit margin improved by 8.84% QoQ.
BEAR CASE
MAXIND recorded a net loss of ₹43 Cr in Q4 2025 and an annual net loss of ₹140 Cr in FY25, alongside a significantly negative ROCE of -24.0%.
The stock price has seen a 19.11% decline over the last year and is currently trading 37.47% off its 52-week high of ₹241.57.
Promoter holding decreased by 0.07% to 49.82% and FII holding decreased by 0.01% to 7.07% QoQ ending March 2026.
ML predictions for Sales growth are weak, with 1-year sales growth ranks ranging from 0.348 to 0.391.
The company's P/B ratio of 1.7 highlights potential overvaluation relative to its book value of ₹89.4, particularly given its negative profit margin of -80.64%.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹60 Cr
+62.91% YoY
NET PROFIT
₹-36 Cr
OPM
-36.35%
+19.73pp YoY
EPS
₹-6.91
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-18.4% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
MAXIND's negative ROCE of -24.0% contrasts sharply with sector peers like APOLLOHOSP (ROCE 20.26%) and NH (ROCE 22.72%), and its Price-to-Sales of 4.33 sits below the PE ratios of profitable peers such as APOLLOHOSP (PE 82.13) and MAXHEALTH (PE 67.07).
PEERPEROCE %
MAXIND-24.0
APOLLOHOSP82.1320.26
MAXHEALTH67.0714.44
FORTIS94.2613.4
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
37
SCORE / 100
Overall
6-axis composite of the sections below.
Performance UNDERPERFORMER 5
Valuation
Growth STRONG 72
Profitability LOW 5
Technicals NEUTRAL 55
Risk MODERATE 50
Key Stats
P/B
1.7
52W HIGH
₹241.57
OFF HIGH
-37.72%
MKT CAP
₹794 Cr
◉ Active Signals
MACDNeutral0.1775
RSI(14)Neutral42.16
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MAXIND and at what entry.

Sign up freeSign in